An observational study in Psoriasis, sponsored by Fundación Pública Andaluza Progreso y Salud. Completed at 5 sites in Spain. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2015-07-20.
Sponsored by Fundación Pública Andaluza Progreso y Salud · Observational
Evaluate the 3-year survival of etanercept in patients over 60 years with psoriasis in moderate / severe plaque and the reasons that led to the abandonment. Besides factors that might have had a positive or negative influence on adherence to treatment and analysis of efficacy (PASI 75) and safety will be identified.
All variables were collected through retrospective review of medical records of patients dermatology unit are made.
1,899 studies on the registry are indexed under Psoriasis; 233 are open to participants now.
This study's enrollment of 70 is below the median of 200 across 396 observational studies indexed under Psoriasis.
Browse Psoriasis studies →Fundación Pública Andaluza Progreso y Salud is the lead sponsor of 28 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients over 60 who received etanercept for the treatment of moderate / severe psoriasis
Exclusion Criteria:
primary ineffectiveness in patients with etanercept treatment
Number of participants not achieve PASI 50 response at 12 weeks
Time frame: 24 weeks
Secondary ineffectiveness in patients with etanercept treatment
Number of participants with Poor adherence to treatment with etanercept",
Time frame: 24 weeks (duration of treatment with etanercept)
Ineffectiveness of treatment in localized lesions in patients with etanercept treatment
Despite having achieved a good response PASI no improvement in critical injuries
Time frame: 24 weeks(duration of treatment with etanercept)
primary ineffectiveness in patients with etanercept treatment
Number of participants not achieve PASI 75 response at 24 weeks
Time frame: 24 weeks
Number of participants with adverse events during treatment with etanercept
Time frame: 24 weeks
Number of participants with disease remission
Time frame: 24 weeks
number of participants with Poor adherence to treatment with etanercept
Time frame: 24 weeks
number of participants with Conditions requiring hospitalization and / or surgery
Time frame: 24 weeks
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Pública Andaluza Progreso y Salud